Bupropion side effects: what 44,278 FDA adverse event reports show
Drug class
Aminoketone antidepressant
Who reports
44,278 reports · 72% serious · 8,963 with death outcome · 66% female
Used for
1. INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets, USP (XL) is an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
What it is
11. DESCRIPTION Bupropion hydrochloride extended-release tablets (XL), is an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents.
Boxed warning
SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
- Outcome field, not a reaction Death is a report outcome, not a reaction term. It is dominated by the underlying illness; see the seriousness profile and the boxed warning instead.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1,152 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Ejection fraction | 139 | 148.0 122.3–179.0ROR 148.4 · χ² 15,290 / p <1e-300 | 110.9 EB05 96.2 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=139 · ♀ 100% (drug 66%) | not reported in cached trials |
| Sensitisation | 180 | 145.7 123.3–172.2ROR 146.3 · χ² 19,598 / p <1e-300 | 110.0 EB05 97.1 · IC025 +6.2 3/3 methods agree | Not in label — unassessed | serious n=179 · ♀ 100% (drug 66%) | not reported in cached trials |
| Postmortem blood drug level increased | 54 | 82.8 62.0–110.6ROR 82.9 · χ² 3,637 / p <1e-300 | 68.8 EB05 54.8 · IC025 +5.0 3/3 methods agree | Lab value / disease marker | serious n=54 · 100% clinician | not reported in cached trials |
| Suspected suicide | 673 | 77.8 71.7–84.4ROR 79.0 · χ² 43,669 / p <1e-300 | 66.7 EB05 62.6 · IC025 +5.9 3/3 methods agree | Labeled (related wording) related wording | serious n=673 · 100% clinician | not reported in cached trials |
| Polycystic ovaries | 178 | 60.4 51.7–70.6ROR 60.7 · χ² 9,159 / p <1e-300 | 53.3 EB05 47.1 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=178 · ♀ 100% (drug 66%) | not reported in cached trials |
| Persistent genital arousal disorder | 26 | 59.4 39.5–89.4ROR 59.5 · χ² 1,273 / p 4e-279 | 51.0 EB05 36.5 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=23 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Asthma exercise induced | 33 | 49.6 34.7–71.0ROR 49.7 · χ² 1,377 / p <1e-300 | 43.9 EB05 32.7 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=33 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Temperature regulation disorder | 191 | 45.3 39.1–52.5ROR 45.5 · χ² 7,501 / p <1e-300 | 41.2 EB05 36.5 · IC025 +5.0 3/3 methods agree | Not in label — unassessed | serious n=187 · ♀ 94% (drug 66%) | not reported in cached trials |
| Electrocardiogram qrs complex prolonged | 446 | 45.2 41.0–49.8ROR 45.6 · χ² 17,527 / p <1e-300 | 41.2 EB05 38.1 · IC025 +5.1 3/3 methods agree | Lab value / disease marker | serious n=446 · 100% clinician | not reported in cached trials |
| Retinitis | 143 | 44.3 37.3–52.6ROR 44.4 · χ² 5,488 / p <1e-300 | 40.3 EB05 35.1 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=143 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Factor v leiden mutation | 33 | 42.7 29.9–61.0ROR 42.8 · χ² 1,194 / p 6e-262 | 38.4 EB05 28.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=33 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Psychiatric decompensation | 161 | 42.5 36.2–50.0ROR 42.7 · χ² 5,945 / p <1e-300 | 38.9 EB05 34.1 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=159 · ♀ 0% (drug 66%) · 91% clinician | not reported in cached trials |
| Obstructive sleep apnoea syndrome | 98 | 35.7 29.1–43.8ROR 35.8 · χ² 3,038 / p <1e-300 | 33.0 EB05 27.9 · IC025 +4.5 3/3 methods agree | Not in label — unassessed | serious n=98 · ♀ 100% (drug 66%) | not reported in cached trials |
| Ejection fraction abnormal | 76 | 31.2 24.7–39.3ROR 31.2 · χ² 2,052 / p <1e-300 | 29.1 EB05 24.0 · IC025 +4.2 3/3 methods agree | Lab value / disease marker | serious n=76 · ♀ 100% (drug 66%) | not reported in cached trials |
| Drug specific antibody | 83 | 30.6 24.5–38.2ROR 30.7 · χ² 2,204 / p <1e-300 | 28.6 EB05 23.8 · IC025 +4.3 3/3 methods agree | Lab value / disease marker | serious n=83 · ♀ 100% (drug 66%) | not reported in cached trials |
| Lupus vulgaris | 71 | 30.0 23.6–38.1ROR 30.0 · χ² 1,842 / p <1e-300 | 28.0 EB05 23.0 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=71 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Anti-cyclic citrullinated peptide antibody | 39 | 29.3 21.2–40.5ROR 29.4 · χ² 977 / p 7e-215 | 27.3 EB05 20.9 · IC025 +3.8 3/3 methods agree | Lab value / disease marker | serious n=39 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Nephrectomy | 86 | 29.1 23.4–36.2ROR 29.2 · χ² 2,170 / p <1e-300 | 27.3 EB05 22.8 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=84 · ♀ 100% (drug 66%) | not reported in cached trials |
| Completed suicide (death by suicide) | 4,614 | 27.4 26.7–28.2ROR 30.5 · χ² 111,396 / p <1e-300 | 26.0 EB05 25.3 · IC025 +4.6 3/3 methods agree | Outcome field, not a reaction | serious PRR 20.8 · 99% clinician | not reported in cached trials |
| Serotonin syndrome | 889 | 23.0 21.6–24.6ROR 23.5 · χ² 17,856 / p <1e-300 | 22.0 EB05 20.8 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious PRR 17.8 · 94% clinician | not reported in cached trials |
| Oesophageal spasm | 84 | 22.6 18.1–28.1ROR 22.6 · χ² 1,631 / p <1e-300 | 21.5 EB05 17.9 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=84 · ♀ 100% (drug 66%) | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Rhinitis allergic | 194 | 21.6 18.7–24.9ROR 21.7 · χ² 3,621 / p <1e-300 | 20.6 EB05 18.3 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=192 · ♀ 95% (drug 66%) | not reported in cached trials |
| Depressive symptom | 152 | 21.4 18.2–25.1ROR 21.4 · χ² 2,803 / p <1e-300 | 20.4 EB05 17.8 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=147 · ♀ 26% (drug 66%) | not reported in cached trials |
| Brugada syndrome | 44 | 21.2 15.7–28.7ROR 21.3 · χ² 792 / p 1e-174 | 20.2 EB05 15.6 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=44 · 100% clinician | not reported in cached trials |
| Granuloma skin | 35 | 20.8 14.9–29.2ROR 20.9 · χ² 614 / p 8e-136 | 19.8 EB05 14.8 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=35 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Foetal death | 216 | 20.5 17.9–23.5ROR 20.6 · χ² 3,829 / p <1e-300 | 19.7 EB05 17.6 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=216 · ♀ 100% (drug 66%) | not reported in cached trials |
| Psychomotor skills impaired | 107 | 20.1 16.5–24.3ROR 20.1 · χ² 1,840 / p <1e-300 | 19.2 EB05 16.3 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=105 · ♀ 0% (drug 66%) · 100% clinician | not reported in cached trials |
| Food allergy | 297 | 19.3 17.2–21.7ROR 19.5 · χ² 4,944 / p <1e-300 | 18.6 EB05 16.9 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=288 · ♀ 100% (drug 66%) | not reported in cached trials |
| Bone erosion | 136 | 18.9 15.9–22.4ROR 18.9 · χ² 2,195 / p <1e-300 | 18.1 EB05 15.7 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=136 · ♀ 100% (drug 66%) · 100% clinician | not reported in cached trials |
| Areflexia | 103 | 18.8 15.5–22.9ROR 18.9 · χ² 1,655 / p <1e-300 | 18.1 EB05 15.3 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=102 · ♀ 87% (drug 66%) · 100% clinician | not reported in cached trials |
| Rheumatoid factor positive | 220 | 18.7 16.4–21.4ROR 18.8 · χ² 3,534 / p <1e-300 | 18.0 EB05 16.1 · IC025 +3.9 3/3 methods agree | Lab value / disease marker | serious n=220 · ♀ 100% (drug 66%) · 96% clinician | not reported in cached trials |
| Distributive shock | 83 | 18.4 14.8–23.0ROR 18.5 · χ² 1,301 / p 4e-285 | 17.7 EB05 14.7 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=83 · ♀ 43% (drug 66%) · 100% clinician | not reported in cached trials |
| Pupil fixed | 62 | 17.4 13.5–22.4ROR 17.4 · χ² 909 / p 6e-200 | 16.7 EB05 13.5 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=62 · 100% clinician | not reported in cached trials |
| Hyperreflexia | 119 | 16.6 13.9–20.0ROR 16.7 · χ² 1,674 / p <1e-300 | 16.0 EB05 13.8 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=118 · 100% clinician | not reported in cached trials |
| Depression suicidal | 116 | 16.4 13.6–19.7ROR 16.4 · χ² 1,605 / p <1e-300 | 15.8 EB05 13.5 · IC025 +3.6 3/3 methods agree | Labeled (related wording) related wording | serious n=116 · ♀ 0% (drug 66%) | not reported in cached trials |
| Bezoar | 45 | 15.9 11.8–21.5ROR 16.0 · χ² 595 / p 1e-131 | 15.3 EB05 11.8 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=45 · 100% clinician | not reported in cached trials |
| Rebound acid hypersecretion | 96 | 15.3 12.5–18.7ROR 15.3 · χ² 1,226 / p 7e-269 | 14.7 EB05 12.4 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=96 | not reported in cached trials |
| Hallucinations, mixed | 131 | 15.2 12.8–18.1ROR 15.2 · χ² 1,667 / p <1e-300 | 14.7 EB05 12.7 · IC025 +3.5 3/3 methods agree | Labeled (related wording) related wording | serious n=128 | not reported in cached trials |
| Exposure via ingestion | 79 | 15.1 12.1–18.9ROR 15.1 · χ² 994 / p 2e-218 | 14.6 EB05 12.0 · IC025 +3.4 3/3 methods agree | Reporting / coding artifact | serious n=77 · 100% clinician | not reported in cached trials |
| Pulseless electrical activity | 125 | 14.6 12.2–17.4ROR 14.6 · χ² 1,522 / p <1e-300 | 14.1 EB05 12.1 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=125 | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Bupropion as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (1 of 40 signal terms matched).
- NCT06090461 — Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.) (N=31889, phase n/a; 3 AE terms posted; arms: Contrave/Mysimba; Lorcaserin; Naltrexone and Bupropion (N&B))
- NCT01601704 — Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascul (N=8910, PHASE3; 634 AE terms posted; arms: NB32; Placebo)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Completed suicide (death by suicide) | 4,614 | 27.4 26.7–28.2ROR 30.5 · χ² 111,396 / p <1e-300 | 26.0 EB05 25.3 · IC025 +4.6 3/3 methods agree | Outcome field, not a reaction | serious PRR 20.8 · 99% clinician | not reported in cached trials |
| Toxicity to various agents | 3,687 | 10.6 10.3–11.0ROR 11.5 · χ² 31,641 / p <1e-300 | 10.4 EB05 10.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 8.6 · 97% clinician | not reported in cached trials |
| Drug ineffective (drug did not work) | 3,669 | 1.3 1.3–1.4ROR 1.3 · χ² 303 / p 4e-68 | 1.3 EB05 1.3 · IC025 +0.3 | Reporting / coding artifact | serious PRR 1.9 | not reported in cached trials |
| Fatigue (tiredness) | 2,794 | 1.7 1.6–1.8ROR 1.8 · χ² 843 / p 1e-185 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled (related wording) related wording | serious PRR 1.7 | NCT01601704: 13/4,455 (0.3%) on Bupropion; 1/4,450 (0.0%) control |
| Nausea | 2,437 | 1.5 1.4–1.5ROR 1.5 · χ² 371 / p 7e-83 | 1.5 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | serious PRR 1.5 | NCT01601704: 1/4,455 (0.0%) on Bupropion (serious AE) |
| Off label use (used outside approved label) | 2,435 | 1.3 1.3–1.4ROR 1.3 · χ² 206 / p 4e-47 | 1.3 EB05 1.3 · IC025 +0.3 | Reporting / coding artifact | serious PRR 1.5 | not reported in cached trials |
| Headache | 2,352 | 1.8 1.7–1.9ROR 1.8 · χ² 827 / p 3e-182 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | serious PRR 2.1 | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Depression | 2,232 | 4.7 4.5–4.9ROR 4.9 · χ² 6,420 / p <1e-300 | 4.6 EB05 4.5 · IC025 +2.1 3/3 methods agree | Labeled — boxed warning synonym match | serious PRR 4.3 | NCT01601704: 1/4,450 (0.0%) control (serious AE) |
| Pain | 2,045 | 1.6 1.5–1.6ROR 1.6 · χ² 441 / p 3e-98 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.6 | NCT01601704: 2/4,455 (0.0%) on Bupropion; 3/4,450 (0.1%) control (serious AE) |
| Overdose | 1,935 | 4.3 4.1–4.4ROR 4.4 · χ² 4,828 / p <1e-300 | 4.2 EB05 4.1 · IC025 +2.0 3/3 methods agree | Reporting / coding artifact | serious PRR 4.2 · 91% clinician | not reported in cached trials |
| Anxiety | 1,740 | 2.9 2.8–3.0ROR 3.0 · χ² 2,180 / p <1e-300 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.8 | NCT01601704: 26/4,455 (0.6%) on Bupropion; 8/4,450 (0.2%) control |
| Drug interaction | 1,735 | 5.2 5.0–5.5ROR 5.4 · χ² 5,900 / p <1e-300 | 5.2 EB05 5.0 · IC025 +2.3 3/3 methods agree | Reporting / coding artifact | serious PRR 4.4 · ♀ 35% (drug 66%) | not reported in cached trials |
| Dizziness | 1,667 | 1.6 1.5–1.7ROR 1.6 · χ² 369 / p 1e-82 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.6 | NCT01601704: 4/4,455 (0.1%) on Bupropion; 1/4,450 (0.0%) control (serious AE) |
| Seizure | 1,664 | 7.0 6.6–7.3ROR 7.2 · χ² 8,395 / p <1e-300 | 6.9 EB05 6.6 · IC025 +2.7 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 5.8 · 92% clinician | not reported in cached trials |
| Diarrhoea (diarrhea) | 1,630 | 1.2 1.1–1.3ROR 1.2 · χ² 56 / p 4e-14 | 1.2 EB05 1.2 · IC025 +0.2 | Labeled adverse reaction exact term | serious PRR 1.2 | NCT01601704: 35/4,455 (0.8%) on Bupropion; 21/4,450 (0.5%) control |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Ejection fraction — n=139, PRR 148.0
- Sensitisation — n=180, PRR 145.7
- Polycystic ovaries — n=178, PRR 60.4
- Asthma exercise induced — n=33, PRR 49.6
- Temperature regulation disorder — n=191, PRR 45.3
- Retinitis — n=143, PRR 44.3
- Factor v leiden mutation — n=33, PRR 42.7
- Psychiatric decompensation — n=161, PRR 42.5
- Obstructive sleep apnoea syndrome — n=98, PRR 35.7
- Lupus vulgaris — n=71, PRR 30.0
✓ A hand-written Bradford Hill causality assessment exists for this drug: Bupropion ↔ Seizures.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Bupropion?
In FDA FAERS, the most frequently co-reported reaction terms for Bupropion are toxicity to various agents, fatigue, nausea, headache, depression, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Bupropion have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS; AND NEUROPSYCHIATRIC REACTIONS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. ( 5.1 ) • Monitor for worsening and emergence of suicidal thoughts and behaviors.
Do FAERS signals prove that Bupropion causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 47ceb7e1-b2f7-47f8-8b6a-85eea36606b8, effective 20210101; matched on
openfda.generic_name.exact:"BUPROPION") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,192 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
BUPROPION, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.